Skip to main content

Persistent Atrial Fibrillation

Cardiovascular
4
Pipeline Programs
13
Companies
18
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 18 programs with unclassified modality

Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.

$69.4B marketMature→ Stable30 products15 companies

Key Trends

  • FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
  • SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
  • Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure

Career Verdict

Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Peak15.0yr
#2JARDIANCEGrowing
$8.8B
Boehringer Ingelheim·Peak8.6yr
#3XARELTOStable
$6.3B
Johnson & Johnson·Peak
#4FARXIGAGrowing
$4.3B
AstraZeneca·Peak15.4yr
#5JANUVIADeclining
$4.1B
Merck & Co.·LOE_Approaching1.1yr

Drug Class Breakdown

FXa Inhibitors (Apixaban/Rivaroxaban)
$42.8B(62%)

Mature, stable revenue base

SGLT2 Inhibitors
$13.1B(19%)

Growing in heart failure and renal indications

DPP4 Inhibitors
$4.1B(6%)

Declining as LOE approaches 2027

ARBs and Combination Therapies
$3.4B(5%)

Stable in heart failure management

Endothelin Receptor Antagonists and Prostacyclin Agonists
$1.8B(3%)

Niche pulmonary hypertension market

Career Outlook

Stable

Cardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.

Breaking In

Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.

For Experienced Professionals

Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.

In-Demand Skills

Healthcare economics and payer management (anticoagulation safety monitoring, cost-effectiveness)Real-world evidence generation (postmarket surveillance for FXa inhibitors)Digital health and remote patient monitoring integrationClinical trial execution in large, established patient populationsRegulatory expertise in label expansions (SGLT2 inhibitor indications)

Best For

Commercial/Sales roles (mature market execution)Medical Science Liaisons (managing healthcare provider relationships on established therapies)Clinical Operations/Project Managers (managing large Phase 3/4 programs)Regulatory Affairs (label expansion strategy, patent cliff preparation)Health Economics and Outcomes Research (demonstrating value in competitive anticoagulation market)

Hiring Landscape

$130K-$210K

Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.

1,386
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

Abbott
337Growing
Medtronic
317Growing
Johnson & Johnson
261Stable
Bristol Myers Squibb
52Declining
Edwards Lifesciences
78Growing

By Department

Commercial(34%)
$210K
Clinical Operations(21%)
$180K
Engineering(13%)
$145K
Medical Affairs(1%)
$201K
Research & Development(1%)
$194K

Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.

On Market (1)

Approved therapies currently available

Sanofi
AVAPROApproved
irbesartan
Sanofi
Angiotensin 2 Receptor Blocker [EPC]oral1997
3M Part D

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Boston Scientific
Boston ScientificCA - Valencia
2 programs
1
Farapulse Catheter SystemPhase 41 trial
Pulmonary Vein IsolationN/A1 trial
Active Trials
NCT03835338Withdrawn0Est. Apr 2024
NCT06765356Active Not Recruiting275Est. Mar 2027
Sanofi
SanofiPARIS, France
1 program
1
AVAPRO(irbesartan)PHASE_4Small Molecule1 trial
Active Trials
NCT00613496Unknown60Est. May 2010
AtriCure
AtriCureCA - Pleasanton
1 program
1
AtriCure EPi-Sense-AF Guided Coagulation SystemPhase 41 trial
Active Trials
NCT01984346Completed170Est. Oct 2023
Menarini
MenariniGermany - Dresden
1 program
1
RanolazinePhase 21 trial
Active Trials
NCT01534962Completed241Est. Mar 2014
Abbott
AbbottABBOTT PARK, IL
5 programs
Advisor HD Grid Mapping Catheter, Sensor EnabledN/A1 trial
ICD/CRT implantN/A1 trial
IbutilideN/A1 trial
Standard PVIN/A1 trial
Substrate+mCPVAN/A1 trial
Active Trials
NCT03733392Completed379Est. May 2021
NCT00652522Completed202Est. Jul 2017
NCT01014741Completed200Est. Jan 2015
+2 more trials
Medtronic
MedtronicNJ - Phillipsburg
3 programs
Arctic Front™ Cardiac Cryoablation Catheter SystemN/A1 trial
CryoballoonN/A1 trial
DC CardioversionN/A1 trial
Active Trials
NCT05005949Active Not Recruiting400Est. Jul 2028
NCT03706677Completed69Est. Apr 2023
NCT03907982Completed20Est. Apr 2023
Adagio Medical
Adagio MedicalCA - Laguna Hills
1 program
Adagio AF Cryoablation SystemN/A1 trial
Active Trials
NCT04061603Completed215Est. Aug 2024
Rhine Pharma
Rhine PharmaGermany - Heidelberg
1 program
Beat-to-beat Variability in Persistent Atrial FibrillationN/A1 trial
Active Trials
NCT03092362Completed32Est. Jun 2020
coremap
coremapVT - Burlington
1 program
CoreMap EP Mapping System MappingN/A1 trial
Active Trials
NCT06529978Recruiting245Est. Dec 2026
Rhythm Pharmaceuticals
1 program
CryoballoonN/A
Biotronik
BiotronikGermany - Berlin
1 program
Insertable Cardiac MonitorN/A1 trial
Active Trials
NCT04190186Completed55Est. Feb 2024
MicroPort
MicroPortChina - Shanghai
1 program
a dual energy catheterN/A1 trial
Active Trials
NCT06232798Completed10Est. Apr 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Boston ScientificFarapulse Catheter System
Sanofiirbesartan
MenariniRanolazine
coremapCoreMap EP Mapping System Mapping
MicroPorta dual energy catheter
MedtronicDC Cardioversion
Boston ScientificPulmonary Vein Isolation
MedtronicArctic Front™ Cardiac Cryoablation Catheter System
BiotronikInsertable Cardiac Monitor
Adagio MedicalAdagio AF Cryoablation System
MedtronicCryoballoon
AbbottAdvisor HD Grid Mapping Catheter, Sensor Enabled
Rhine PharmaBeat-to-beat Variability in Persistent Atrial Fibrillation
AbbottStandard PVI
AbbottSubstrate+mCPVA

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 2,923 patients across 18 trials

NCT06765356Boston ScientificFarapulse Catheter System

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

Start: Apr 2025Est. completion: Mar 2027275 patients
Phase 4Active Not Recruiting
NCT00613496Sanofiirbesartan

Irbesartan and Adhesion Molecules in AF

Start: May 2009Est. completion: May 201060 patients
Phase 4Unknown
NCT01534962MenariniRanolazine

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion

Start: Jan 2012Est. completion: Mar 2014241 patients
Phase 2Completed
NCT06529978coremapCoreMap EP Mapping System Mapping

Endocardial Mapping With the CoreMap EP Mapping System

Start: Jul 2024Est. completion: Dec 2026245 patients
N/ARecruiting
NCT06232798MicroPorta dual energy catheter

A Dual Energy Catheter (PFA and RFA) and a PFA Catheter for the Treatment of PeAF

Start: Jan 2024Est. completion: Apr 202510 patients
N/ACompleted
NCT03907982MedtronicDC Cardioversion

Investigation of Therapeutic Ablation Versus Cardioversion for AF

Start: Oct 2021Est. completion: Apr 202320 patients
N/ACompleted
NCT03835338Boston ScientificPulmonary Vein Isolation

WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm

Start: Sep 2021Est. completion: Apr 20240
N/AWithdrawn
NCT05005949MedtronicArctic Front™ Cardiac Cryoablation Catheter System

STOP Persistent AF PAS

Start: Aug 2021Est. completion: Jul 2028400 patients
N/AActive Not Recruiting
NCT04190186BiotronikInsertable Cardiac Monitor

Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation

Start: Jun 2020Est. completion: Feb 202455 patients
N/ACompleted
NCT04061603Adagio MedicalAdagio AF Cryoablation System

iCLAS™ for Persistent Atrial Fibrillation

Start: Dec 2019Est. completion: Aug 2024215 patients
N/ACompleted
NCT03706677MedtronicCryoballoon

FIRE AND ICE II Trial Pilot

Start: Apr 2019Est. completion: Apr 202369 patients
N/ACompleted
NCT03733392AbbottAdvisor HD Grid Mapping Catheter, Sensor Enabled

Advisor HD Grid Observational Study

Start: Jan 2019Est. completion: May 2021379 patients
N/ACompleted
NCT03092362Rhine PharmaBeat-to-beat Variability in Persistent Atrial Fibrillation

Beat-to-beat Variability in Persistent Atrial Fibrillation

Start: Nov 2016Est. completion: Jun 202032 patients
N/ACompleted
NCT02799043AbbottStandard PVI

Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With FIRM Guided Procedures

Start: Jun 2016Est. completion: Jul 2020269 patients
N/ACompleted
NCT02571218AbbottSubstrate+mCPVA

AF Substrate Mapping and Guided Ablation

Start: Jul 2015Est. completion: Feb 201781 patients
N/ACompleted
NCT01984346AtriCureAtriCure EPi-Sense-AF Guided Coagulation System

CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)

Start: Dec 2013Est. completion: Oct 2023170 patients
N/ACompleted
NCT01014741AbbottIbutilide

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Start: Oct 2009Est. completion: Jan 2015200 patients
N/ACompleted
NCT00652522AbbottICD/CRT implant

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Start: Jan 2008Est. completion: Jul 2017202 patients
N/ACompleted

Related Jobs in Cardiovascular

Senior Manufacturing Engineer

BALTBALT
Irvine, California, United States
10h ago
$120K - $130K/yr

Staff Product Development Engineer

Jupiter EndovascularJupiter Endovascular
Menlo Park, CA
11h ago
$160K - $180K/yr

Application Security Engineer

HeartFlowHeartFlow
San Francisco, California
12h ago
$145K - $180K/yr

Senior Software Engineer

HeartFlowHeartFlow
San Francisco, California, United States
12h ago
$180K - $215K/yr

Staff Software Engineer

HeartFlowHeartFlow
San Francisco, California
12h ago
$190K - $250K/yr

Director, Clinical Quality Lead

KardiganKardigan
South San Francisco, California, United States, Princeton, New Jersey, United States
16h ago
$194K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,923 patients
13 companies competing in this space

Related Indications

Hypertension(936)Heart Failure(877)Coronary Artery Disease(769)Atrial Fibrillation(615)Pulmonary Arterial Hypertension(207)Acute Coronary Syndrome(140)Atherosclerosis(123)Aortic Valve Stenosis(121)Pulmonary Hypertension(111)Congestive Heart Failure(94)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.